Long-COVID postural tachycardia syndrome: an American Autonomic Society statement

Satish R Raj, Amy C Arnold, Alexandru Barboi, Victoria E Claydon, Jacqueline K Limberg, Vera-Ellen M Lucci, Mohammed Numan, Amanda Peltier, Howard Snapper, Steven Vernino, American Autonomic Society, Satish R Raj, Amy C Arnold, Alexandru Barboi, Victoria E Claydon, Jacqueline K Limberg, Vera-Ellen M Lucci, Mohammed Numan, Amanda Peltier, Howard Snapper, Steven Vernino, American Autonomic Society

Abstract

COVID-19 is a global pandemic that has had a devastating effect on the health and economy of much of human civilization. While the acute impacts of COVID-19 were the initial focus of concern, it is becoming clear that in the wake of COVID-19, many patients are developing chronic symptoms that have been called Long-COVID. Some of the symptoms and signs include those of postural tachycardia syndrome (POTS). Understanding and managing long-COVID POTS will require a significant infusion of health care resources and a significant additional research investment. In this document from the American Autonomic Society, we outline the scope of the problem, and the resources and research needed to properly address the impact of Long-COVID POTS.

Keywords: COVID; Long COVID; Position statement; Postural tachycardia syndrome.

Conflict of interest statement

SRR has grant support from the Canadian Institutes of Health Research (Ottawa, Canada) and Dysautonomia International (East Moriches, NY, USA). SRR is a consultant for Lundbeck LLC and Theravance Biopharma, and serves as DSMB chair for a phase 2 study run by Arena Pharmaceuticals. SRR has received compensation for editorial activities (Associate Editor) with Autonomic Neuroscience—Basic and Clinical. ACA: Consultant for National Vaccine Injury Compensation Program, U.S. Department of Health and Human Services; research grant from Dysautonomia International. AB: None. VEC: Research grants from the Heart and Stroke Foundation of Canada, Craig H Nielsen Foundation, and International Collaboration on Repair Discoveries. JKL: None. MN: None. VEML: None. AP: None. HS: None. SV: SV has received research support from Biohaven, Dysautonomia International, Genentech, Grifols, Rex Griswold Foundation, and Athena/Quest Diagnostics (through a licensing contract) and personal compensation for consulting for Catalyst, Sage and Alterity.

References

    1. Centers for Disease Control and Prevention (2021) COVID-19 Cases, Data and Surveillance. . Accessed 16 Feb 2021
    1. World Health Organization (2021) Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. . Accessed 16 Feb 2021
    1. World Health Organization (2021) WHO coronavirus (COVID-19) dashboard. . Accessed 8 Mar 2021
    1. National Institute for Health and Care Excellence (NICE) (2021) COVID-19 rapid guideline: managing the long-term effects of COVID-19. . Accessed 16 Feb 2021
    1. Mayo Clinic (2021) COVID-19 (coronavirus): long-term effects. . Accessed 20 Feb 2021
    1. Goldstein DS. The possible association between COVID-19 and postural orthostatic tachycardia syndrome. Heart Rhythm. 2020 doi: 10.1016/j.hrthm.2020.12.007.
    1. Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J Innov Card Rhythm Manag. 2020;11:4302–4304. doi: 10.19102/icrm.2020.111102.
    1. Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30:449–451. doi: 10.1007/s10286-020-00727-9.
    1. Umapathi T, Poh MQW, Fan BE, et al. Acute hyperhidrosis and postural tachycardia in a COVID-19 patient. Clin Auton Res. 2020;30:571–573. doi: 10.1007/s10286-020-00733-x.
    1. Reddy S (2020) For COVID long-haulers, a little-known diagnosis offers possible treatments—and new challenges. Wall Street Journal.
    1. Gulliver Caspersen S (2020) When the doctor is a COVID ‘long hauler.’ New York Times.
    1. Yong E (2020) Long-Haulers Are redefining COVID-19. The Atlantic.
    1. Raj SR, Guzman JC, Harvey P, et al. Canadian cardiovascular society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020;36:357–372. doi: 10.1016/j.cjca.2019.12.024.
    1. Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome—insights from a large cross-sectional online community-based survey. J Intern Med. 2019;286:438–448. doi: 10.1111/joim.12895.
    1. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117:11727–11734. doi: 10.1073/pnas.2003138117.
    1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052.
    1. Fraiman P, Freire M, Moreira-Neto M, Godeiro-Junior C. Hemorrhagic stroke and COVID-19 infection: coincidence or causality? NeurologicalSci. 2020;21:100274. doi: 10.1016/j.ensci.2020.100274.
    1. Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain–Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2020 doi: 10.1136/jnnp-2020-324837.
    1. Arcila-Londono X, Lewis RA. Guillain–Barré syndrome. Semin Neurol. 2012;32:179–186. doi: 10.1055/s-0032-1329196.
    1. Fu Q, Vangundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2010;55:2858–2868. doi: 10.1016/j.jacc.2010.02.043.
    1. Gibbons CH, Silva G, Freeman R. Cardiovascular exercise as a treatment of postural orthostatic tachycardia syndrome: a pragmatic treatment trial. Heart Rhythm. 2021 doi: 10.1016/j.hrthm.2021.01.017.
    1. National Institutes of Health Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative. . Accessed 20 Feb 2021

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다